ArticleNeurology and therapy2026

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.

Jerry R Mendell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.